US mRNA player Arcturus buys Belgian biotech MyNeo
What's the deal? Nasdaq-listed Arcturus Therapeutics has acquired MyNeoDealroom has a profile for this one. Try Dealroom →, a Ghent-based bioinformatics company. The deal was announced in September 2026; the purchase price was not disclosed.
Who's who? MyNeo specialises in bioinformatics, while Arcturus is a US-based mRNA specialist. The acquisition puts the Belgian biotech into American hands.
The signal: The deal marks another cross-border pickup of European biotech expertise by a US player, as mRNA developers seek out specialist data and computing capabilities.
Read more: tijd.be
Image credit: Generated with Gemini
